Hong Kong at a glance
- Population
- 7.5 million 2025
- Life expectancy at birth
- 85.4 years, 2024
- People aged 65 and over
- 23.7 % of people, 2025
Updated
Reviewed by Vidhi Upadhyay
Hong Kong Hyperuricemia Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$4.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $4.0 Mn | — | — |
| 2025 (base) | $4.3 Mn | +$0.3 Mn | — |
| 2026 (forecast) | $4.7 Mn | +$0.4 Mn | +8.4% |
| 2027 (forecast) | $5.1 Mn | +$0.4 Mn | +17.5% |
| 2028 (forecast) | $5.5 Mn | +$0.4 Mn | +27.4% |
| 2029 (forecast) | $6.0 Mn | +$0.5 Mn | +38.1% |
| 2030 (forecast) | $6.5 Mn | +$0.5 Mn | +49.7% |
| 2031 (forecast) | $7.1 Mn | +$0.5 Mn | +62.2% |
| 2032 (forecast) | $7.6 Mn | +$0.6 Mn | +75.9% |
| 2033 (forecast) | $8.3 Mn | +$0.6 Mn | +90.6% |
| 2034 (forecast) | $9.0 Mn | +$0.7 Mn | +106.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $4.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $9.0 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.4% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug class, indication and end user (see all) |
| Key players | Takeda Pharmaceutical Company Ltd, Amgen Inc., Teijin Pharma, Fuji Yakuhin, Arthrosi Therapeutics (see all) |
| Regulator in Hong Kong | Drug OfficeSource: Drug Office, Department of Health. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Hyperuricemia drugs lower high uric acid in the blood, which can cause gout and kidney stones and is linked to heart and kidney disease.
Key segments of the hyperuricemia Drugs market include drug class (Xanthine Oxidase Inhibitors, URAT1 Inhibitors and Recombinant Uricase) and indication (Gout, Chronic Kidney Disease and Tumor Lysis Syndrome).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the hyperuricemia Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the hyperuricemia Drugs market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the hyperuricemia Drugs market. Long-term safety data and lifestyle support are still needed for many patients.
The hyperuricemia Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health.[1] Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.[2]
[1] Drug Office, Department of Health. Checked 14 Nov 2026.
[2] Hospital Authority. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for hyperuricemia Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Hong Kong.
What doctors and scientists are doing in Hyperuricemia Drugs right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.
Hong Kong · 1 shared keyword
Hong Kong
Hong Kong
Hong Kong
Hong Kong
Hong Kong
Medical Devices · Hong Kong
Medical Devices · Hong Kong
Medical Devices · Hong Kong
Medical Devices · Hong Kong
Medical Devices · Hong Kong
Medical Devices · Hong Kong